ErbB2/Her2 Proteins
We offer ErbB2/Her2 Peptides and ErbB2/Her2 Proteins for use in common research applications: Blocking/Neutralizing, Control, ELISA, Functional, Protein Array, SDS-Page, Western Blot. Each ErbB2/Her2 Peptide and ErbB2/Her2 Protein is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. Our ErbB2/Her2 Peptides and ErbB2/Her2 Proteins can be used in a variety of model species: Human. Use the list below to choose the ErbB2/Her2 Peptide and ErbB2/Her2 Protein which is most appropriate for your research; you can click on each one to view full technical details, images, references, reviews and related products. Choose from our ErbB2/Her2 Peptides and Proteins.
Alternate Names for ErbB2/Her2 Proteins
ErbB2/Her2 protein, ERBB2 protein, c-erb B2/neu protein protein, CD340 antigen protein, CD340 protein, EC 2.7.10 protein, HER-2 protein, HER2EC 2.7.10.1 protein, herstatin protein, Metastatic lymph node gene 19 protein protein, MLN 19 protein, MLN19 protein, NEUHER-2/neu protein, neuroblastoma/glioblastoma derived oncogene homolog protein, NGLTKR1 protein, p185erbB2 protein, Proto-oncogene c-ErbB-2 protein, Proto-oncogene Neu protein, receptor tyrosine-protein kinase erbB-2 protein, Tyrosine kinase-type cell surface receptor HER2 protein, v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2(neuro/glioblastoma derived oncogene homolog) protein, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastomaderived oncogene homolog (avian) protein
16 Results for "erbb2-her2" in Peptides and Proteins
1129-ER) blocks anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer proliferation. The ED50 for this effect is 0.3-1.2 µg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, MAB9589)." alt="Recombinant human ErB2 / Her2 (1129-ER) blocks anti-ErbB2 mediated inhibition of SK-BR-3 human breast cancer proliferation. The ED50 for this effect is 0.3-1.2 µg/mL in the presence of 0.6 µg/mL Anti-Human ErbB2/Her2 Monoclonal Antibody (Trastuzumab, MAB9589)." class="big_thumb" />
MAB9589) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ErbB2/Her2 Fc Chimera Avi-tag (Catalog # AVI1129) binds with an ED50 of 10-60 ng/mL." alt="When Human ErbB2/Her2 (Trastuzumab) Antibody (Catalog # MAB9589) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ErbB2/Her2 Fc Chimera Avi-tag (Catalog # AVI1129) binds with an ED50 of 10-60 ng/mL." class="big_thumb" />
MAB9589) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ErbB2/Her2 Avi-tag His-tag Protein (Catalog # AVI11356) binds with an ED50 of 0.500‑6.00 ng/mL." alt="When Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody (MAB9589) is immobilized at 0.5 µg/mL (100 µL/well), Biotinylated Recombinant Human ErbB2/Her2 Avi-tag His-tag Protein (Catalog # AVI11356) binds with an ED50 of 0.500‑6.00 ng/mL." class="big_thumb" />
MAB9589) with an ED50 of 0.500-6.00 ng/mL." alt="In a functional ELISA, Biotinylated Recombinant Human ErbB2/Her2 Fc Chimera Protein (Catalog # BT1129) binds to Human ErbB2/Her2 (Research Grade Trastuzumab Biosimilar) Antibody (MAB9589) with an ED50 of 0.500-6.00 ng/mL." class="big_thumb" />
MAB9589)." alt="Recombinant Cynomolgus Monkey ErbB2/Her2 His-tag Protein (Catalog # 10613-ER) blocks anti-ErbB2 mediated inhibition of the SK-BR-3 human breast cancer cell line proliferation. The ED50 is 0.7-7 μg/mL in the presence of 0.6 μg/mL Trastuzumab (Human ErbB2/Her2 Antibody, MAB9589)." class="big_thumb" />
10526-ER) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 115-140 kDa and 230-280 kDa, respectively." alt="2 μg/lane of Recombinant Cynomolgus Monkey ErbB2/Her2 Fc Protein (10526-ER) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 115-140 kDa and 230-280 kDa, respectively." class="big_thumb" />
MAB9589) mediated inhibition of the SK-BR-3 human breast cancer cell line proliferation. The ED50 is 0.3-1.2 µg/mL in the presence of 0.6 µg/mL antibody (Trastuzumab, Catalog # 
![SDS-Page: Recombinant Human ErbB2/Her2 Protein [NBP2-59653] - 15% SDS-PAGE (3ug)](http://images.novusbio.com/fullsize/Recombinant-Human-ErbB2-Her2-Protein-SDS-Page-NBP2-59653-img0001.jpg "SDS-Page: Recombinant Human ErbB2/Her2 Protein [NBP2-59653] - 15% SDS-PAGE (3ug)")
